Business Context and Reporting Period
This Form 8-K, filed on September 11, 2023, by First Light Acquisition Group, Inc. ("FLAG"), reports the anticipated consummation of a business combination with Calidi Biotherapeutics, Inc. ("Calidi"). The transaction is scheduled to close on September 12, 2023. Upon completion, FLAG will change its name to Calidi Biotherapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either entity. This report focuses exclusively on the corporate event of the merger.
Material Changes
- Corporate Identity: The registrant will change its name from First Light Acquisition Group, Inc. to Calidi Biotherapeutics, Inc.
- Trading Symbols: Post-combination common stock and warrants are expected to trade on the NYSE American under the ticker symbols "CLDI" and "CLDI WS," respectively, commencing September 13, 2023.
- Transaction Status: The business combination, governed by a Merger Agreement dated January 9, 2023, is moving from announcement to anticipated consummation.
Outlook, Risks, and Management Commentary
Management has announced the expected closing date of the Business Combination via a press release attached as Exhibit 99.1. The filing includes standard forward-looking statements regarding the transaction's completion and the commencement of trading under new symbols. No specific risks, contingencies, or unusual items are detailed within the body of this specific 8-K text beyond the inherent uncertainties of closing a merger.
Investor Verification Checklist
- Verify the official closing of the merger on September 12, 2023.
- Confirm the commencement of trading under the new ticker symbols "CLDI" and "CLDI WS" on September 13, 2023.
- Review the attached Press Release (Exhibit 99.1) for detailed terms and forward-looking statements.
- Check subsequent filings for the post-combination financial statements and capital structure.